HLA class I ABC Polyclonal antibody
HLA class I ABC Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human
Applications
WB, IHC, IF/ICC, IP, ELISA and More (4)
Conjugate
Unconjugated
验证数据展示
经过测试的应用
| Positive WB detected in | A549 cells, HEK-293 cells, HeLa cells, HepG2 cells, NCI-H1299 cells |
| Positive IP detected in | HepG2 cells |
| Positive IHC detected in | human tonsillitis tissue, human stomach cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HepG2 cells |
Planning an IHC experiment? We recommend our IHCeasy HLA-A Ready-To-Use IHC Kit. HLA-A primary antibody included.
Planning an IF experiment? We recommend our CoraLite® Plus 488 and CoraLite®555 conjugated versions of this antibody.
推荐稀释比
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:12000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:500-1:2000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
15240-1-AP targets HLA class I ABC in WB, IHC, IF/ICC, IP, CoIP, RIP, ELISA, Cell treatment applications and shows reactivity with human samples.
| Tested Applications | WB, IHC, IF/ICC, IP, ELISA Application Description |
| Cited Applications | WB, IHC, IF, IP, CoIP, RIP, Cell treatment |
| Tested Reactivity | human |
| Cited Reactivity | human |
| Immunogen | HLA class I ABC fusion protein Ag7370 种属同源性预测 |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Full Name | major histocompatibility complex, class I, A |
| Synonyms | HLA-A, Human leukocyte antigen A, HLA class I histocompatibility antigen, A alpha chain, HLA class I (HLA-A), HLA class I |
| Calculated Molecular Weight | 41 kDa |
| Observed Molecular Weight | 44 kDa |
| GenBank Accession Number | BC003069 |
| Gene Symbol | HLA-A |
| Gene ID (NCBI) | 3105 |
| RRID | AB_1557426 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P04439 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
Human major histocompatibility complex (MHC) antigens, also referred to as human leukocyte antigens (HLA), are encoded by genes located on the short arm of chromosome 6 (6p21.3). There are two classes of HLA antigens: class I (HLA-A, B and C) and class II (HLA-D). This class I molecules are polymorphic membrane glycoproteins composed of a heavy (alpha) chain (44 kDa) which is encoded by a HLA class I gene (HLA-A, B or C), and β2-microglobulin light (beta) chain (12 kDa). They are involved in the presentation of foreign antigens to the immune system. (PMID: 667938; 3375250)
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for HLA class I ABC antibody 15240-1-AP | Download protocol |
| IHC protocol for HLA class I ABC antibody 15240-1-AP | Download protocol |
| IF protocol for HLA class I ABC antibody 15240-1-AP | Download protocol |
| IP protocol for HLA class I ABC antibody 15240-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Cell Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. | ||
ACS Appl Mater Interfaces Self-Assembly of a Multifunction DNA Tetrahedron for Effective Delivery of Aptamer PL1 and Pcsk9 siRNA Potentiate Immune Checkpoint Therapy for Colorectal Cancer. | ||
J Immunother Cancer MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. | ||
J Immunother Cancer THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy. |
